You are here

Menlo Therapeutics

Peninsula biotech coughs up 40 percent of its value on failed clinical trial

Peninsula biotech coughs up 40 percent of its value on failed clinical trial

Bizjournals.com

clinical trials

Menlo Therapeutics

Flag link:

Nasdaq Exec 'Even More Bullish' On Biotech IPOs As New Entries Soar

Nasdaq Exec 'Even More Bullish' On Biotech IPOs As New Entries Soar

Forbes

ARMO BioSciences

Menlo Therapeutics

Flag link:

In an end-of-year IPO blitz, 4 biotechs pitch new offerings totaling $370M

In an end-of-year IPO blitz, 4 biotechs pitch new offerings totaling $370M

Endpoints

ARMO BioSciences

Menlo Therapeutics

Solid Biosciences

Flag link: